ACLS
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Brook, I
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Brook, I
Annals of Clinical and Laboratory Science, Vol 19, Issue 5, 360-376
Copyright © 1989 by Association of Clinical Scientists


Articles

Pathogenicity of the Bacteroides fragilis group

I Brook

The Bacteroides fragilis group is one of the most important pathogens in polymicrobial infections. The distribution of the different members of the B. fragilis group in clinical infections varies. Bacteroides fragilis accounts for 63 percent of all the group isolates, Bacteroides thetaiotaomicron for 14 percent, Bacteroides vulgatus and Bacteroides ovatus for seven percent each, Bacteroides distasonis for six percent and Bacteroides uniformis for two percent. All members of the group induced bacteremia that was associated with an average mortality of 27 percent. The B. fragilis group resist beta lactam antibiotics by producing the enzyme beta-lactamase. This enzyme can be detected in abscess fluid, and can interfere with the eradication of other bacteria that are susceptible to penicillins and cephalosporins. All members of the B. fragilis group can become encapsulated during an inflammatory process as was demonstrated in a subcutaneous abscess model in mice. Non-encapsulated strains can become encapsulated with the assistance of their aerobic counterparts. These encapsulated strains are more virulent to the host than non-encapsulated strains. This increased virulence can be demonstrated by a higher rate of induction of bacteremia, and a greater enhancement of growth of other bacteria in mixed infection. Antimicrobial therapy directed only at the eradication of the aerobic bacteria did not prevent encapsulation, or reduce the number of Bacteroides species. The virulence of all members of the B. fragilis group highlights the need to direct antimicrobial therapy against all members of this group.


This article has been cited by other articles:


Home page
MicrobiologyHome page
E. Vanterpool, F. Roy, W. Zhan, S. M. Sheets, L. Sangberg, and H. M. Fletcher
VimA is part of the maturation pathway for the major gingipains of Porphyromonas gingivalis W83.
Microbiology, November 1, 2006; 152(Pt 11): 3383 - 3389.
[Abstract] [Full Text] [PDF]


Home page
Infect. Immun.Home page
K. P. Robertson, C. J. Smith, A. M. Gough, and E. R. Rocha
Characterization of Bacteroides fragilis Hemolysins and Regulation and Synergistic Interactions of HlyA and HlyB
Infect. Immun., April 1, 2006; 74(4): 2304 - 2316.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
Z. Wang and S. J. Benkovic
Purification, Characterization, and Kinetic Studies of a Soluble Bacteroides fragilis Metallo-beta -lactamase That Provides Multiple Antibiotic Resistance
J. Biol. Chem., August 28, 1998; 273(35): 22402 - 22408.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1989 by the Association of Clinical Scientists.